![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Oxford Biomedica Signs Five-Year Collaboration for COVID-19 Vaccine Manufacturing
Oxford Biomedica Signs Five-Year Collaboration for COVID-19 Vaccine Manufacturing
![signature.gif](https://www.fdanews.com/ext/resources/test/Device_Images2/signature.gif?t=1596243440&width=430)
Oxford Biomedica has signed a five-year collaboration agreement with the Vaccines Manufacturing and Innovation Center (VMIC) to manufacture viral vector-based vaccines.
The VMIC will provide manufacturing equipment to scale up the manufacturing of AstraZeneca’s COVID-19 vaccine, AZD1222.
The agreement may be expanded for Oxford Biomedica to provide manufacturing capacity for other novel viral-vector vaccine candidates.
Upcoming Events
-
21Oct